Pretransplant Antifibrotic Therapy Is Associated with Resolution of Primary Graft Dysfunction.
作者信息
Combs Michael P, Fitzgerald Linda J, Wakeam Elliot, Lyu Dennis M, O'Dwyer David N
机构信息
University of Michigan Ann Arbor, Michigan.
出版信息
Ann Am Thorac Soc. 2022 Feb;19(2):335-338. doi: 10.1513/AnnalsATS.202106-736RL.
Abstract
摘要
相似文献
1
Pretransplant Antifibrotic Therapy Is Associated with Resolution of Primary Graft Dysfunction.移植前抗纤维化治疗与原发性移植物功能障碍的缓解相关。
Ann Am Thorac Soc. 2022 Feb;19(2):335-338. doi: 10.1513/AnnalsATS.202106-736RL.
2
Time to think out of the (ice) box.
Curr Opin Organ Transplant. 2010 Apr;15(2):147-9. doi: 10.1097/MOT.0b013e328336959f.
3
Survey of Lung Transplant Community's Views on Primary Graft Dysfunction.肺移植群体对原发性移植物功能障碍看法的调查
Am J Transplant. 2016 Feb;16(2):724-6. doi: 10.1111/ajt.13552. Epub 2016 Jan 6.
4
Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation.吡非尼酮对接受单肺移植的特发性肺纤维化患者具有有益作用。
Am J Transplant. 2019 Aug;19(8):2358-2365. doi: 10.1111/ajt.15378. Epub 2019 Apr 29.
5
The impact of pretransplant donor-specific antibodies on graft outcome in renal transplantation: a six-year follow-up study.移植前供体特异性抗体对肾移植移植物结局的影响：一项六年随访研究。
Clinics (Sao Paulo). 2012;67(4):355-61. doi: 10.6061/clinics/2012(04)09.
6
Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
Transplantation. 2004 Oct 27;78(8):1212-7. doi: 10.1097/01.tp.0000138100.72757.ba.
7
Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.国际心肺移植学会原发性肺移植功能障碍工作组报告第四部分：预防与治疗：2016年国际心肺移植学会共识组声明
J Heart Lung Transplant. 2017 Oct;36(10):1121-1136. doi: 10.1016/j.healun.2017.07.013. Epub 2017 Jul 21.
8
Fetuin-A pretransplant serum levels, kidney allograft function and rejection episodes: a 3-year posttransplantation follow-up.移植前血清胎球蛋白 A 水平、肾移植功能和排斥反应发作：移植后 3 年随访。
Kidney Blood Press Res. 2011;34(5):328-33. doi: 10.1159/000327848. Epub 2011 May 26.
9
Effect of pretransplant erythropoietin therapy on renal allograft outcome.
Transplantation. 1996 Oct 15;62(7):1026-8. doi: 10.1097/00007890-199610150-00024.
10
Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection.移植前CD4辅助功能和白细胞介素10反应可预测急性肾移植排斥反应的风险。
Transplantation. 1996 Dec 15;62(11):1606-14. doi: 10.1097/00007890-199612150-00014.
引用本文的文献
1
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis.抗纤维化治疗对特发性肺纤维化患者肺移植结局的影响。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231165912. doi: 10.1177/17534666231165912.
2
A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者尼达尼布安全性的真实世界数据叙事性综述。
Adv Ther. 2023 May;40(5):2038-2050. doi: 10.1007/s12325-023-02454-9. Epub 2023 Mar 16.
本文引用的文献
1
Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT.慢性肺移植功能障碍：定义、诊断标准及治疗方法——国际心肺移植学会肺委员会共识报告
J Heart Lung Transplant. 2019 May;38(5):493-503. doi: 10.1016/j.healun.2019.03.009. Epub 2019 Apr 3.
2
Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation.吡非尼酮对接受单肺移植的特发性肺纤维化患者具有有益作用。
Am J Transplant. 2019 Aug;19(8):2358-2365. doi: 10.1111/ajt.15378. Epub 2019 Apr 29.
3
Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative.肺纤维化患者接受抗纤维化治疗期间行肺移植术后吻合口裂开风险：澳大利亚肺移植协作组的经验。
J Heart Lung Transplant. 2019 May;38(5):553-559. doi: 10.1016/j.healun.2019.02.005. Epub 2019 Feb 12.
4
Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model.吡非尼酮可减轻大鼠肺缺血再灌注损伤。
J Thorac Cardiovasc Surg. 2019 Jul;158(1):289-296. doi: 10.1016/j.jtcvs.2018.08.098. Epub 2018 Sep 28.
5
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.国际心肺移植学会原发性肺移植功能障碍工作组报告，第一部分：定义与分级——2016年国际心肺移植学会共识组声明
J Heart Lung Transplant. 2017 Oct;36(10):1097-1103. doi: 10.1016/j.healun.2017.07.021. Epub 2017 Jul 26.
6
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy.曾接受抗纤维化治疗的特发性肺纤维化患者的肺移植结局
J Heart Lung Transplant. 2017 Jul 5. doi: 10.1016/j.healun.2017.07.002.
7
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series.特发性肺纤维化中使用抗纤维化药物过渡到肺移植的安全性和有效性：病例系列
BMC Pulm Med. 2016 Nov 18;16(1):156. doi: 10.1186/s12890-016-0308-z.
8
Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.潜伏类分析确定了肺移植后原发性移植物功能障碍的不同表型。
Chest. 2013 Aug;144(2):616-622. doi: 10.1378/chest.12-1480.
9
Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.急性细胞排斥是闭塞性细支气管炎综合征的一个风险因素，与移植后基础 FEV1 无关。
J Heart Lung Transplant. 2009 Sep;28(9):888-93. doi: 10.1016/j.healun.2009.04.022.
10
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.1996年肺移植排斥反应诊断命名标准化工作方案的修订版。
J Heart Lung Transplant. 2007 Dec;26(12):1229-42. doi: 10.1016/j.healun.2007.10.017.
Zotero 插件